Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single ascending dose study of DCR-PHXC in healthy volunteers and adults with primary hyperoxaluria
NL-OMON46435Phase 1Not yet recruiting
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Mar 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-blind trial of nedosiran in Primary hyperoxaluria (PH), sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoint: Safety and tolerability of single doses of DCR-PHXC. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on NL-OMON46435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46435.